prompt_version: stage1-v184-20260502
model_info: claude-sonnet-4-6

target_title:   Asymmetric Synthesis of Quaternary Hydantoins via a Palladium-Catalyzed Aza-Heck Cyclization
target_authors: Ellie A. Meck, Humair M. Omer, Montana J. Edwards, Temidayo D. Idowu, Mariah L. Murray, Katerina M. Korch, and Donald A. Watson
target_start:   page 1: [REDACTED: paper boundary quote; see Tier 9]
target_end:     end of document

[Turn 1: Agent V1]
field: Asymmetric synthetic organometallic chemistry / palladium-catalyzed asymmetric catalysis
field_rationale: BIB-3 (J. Am. Chem. Soc.) and BIB-1 (aza-Heck cyclization) point to synthetic organometallic chemistry; S0-4 identifies Pd-catalyzed intramolecular cyclization with a chiral phosphoramidite ligand as the primary methodology, placing the subfield specialization in enantioselective transition-metal catalysis.

V1-Q1 | P2:L*col (right col, para beginning "A more focused screen") | [REDACTED: verbatim source quotation; see the source paper via its DOI] | What structural features of L1 distinguish it from the other 47 screened phosphoramidite and phosphite ligands such that it is "uniquely effective," and does the paper provide any structure–activity relationship analysis from the 48-ligand screen? | medium | T2 [paper-grounded inference: the paper reports only that L1 was best without explaining why]

V1-Q2 | P3:Table1 footnote a | [REDACTED: verbatim source quotation; see the source paper via its DOI] | The paper reports 94% assay yield for hydantoin 5 at Table 1 entry 5 (0.1 mmol scale) but 87% isolated yield on 0.5 mmol scale in Scheme 3 — what accounts for this discrepancy, and is the mass balance fully rationalized (i.e., what fraction corresponds to byproduct 26 and other uncharacterized side products)? | low | T1

V1-Q3 | P3:Scheme 3 footnote a | [REDACTED: verbatim source quotation; see the source paper via its DOI] | The scope table (Scheme 3) does not report the amount of the aza-Wacker byproduct 26 for each substrate — is byproduct 26 formed in varying amounts across the substrate scope, and what is the byproduct distribution for the subset of examples where only NMR yield is reported (footnote b)? | medium | T2

V1-Q4 | P3:right col, para beginning "We next examined the role" | [REDACTED: verbatim source quotation; see the source paper via its DOI] | The paper attributes the failure of N-Ph substrate 20 to electronic factors (distinct from the conformational explanation for N-H), but provides only ground-state energy calculations — what experimental evidence (e.g., Hammett linear free-energy correlation, competing coordination studies, or spectroscopic probes) distinguishes an electronic origin from a steric or coordination-poisoning origin for the N-Ph failure? | medium | T2

V1-Q5 | P3:right col, para ending "Collectively, these results suggest" | [REDACTED: verbatim source quotation; see the source paper via its DOI] | Is there direct evidence for the mode of interaction between the 2-phenethyl aromatic group and the palladium-chiral ligand complex? Were substrates with varied arene electronics (electron-rich, electron-poor) or chain length (benzyl, 3-phenylpropyl) on the pendant nitrogen investigated to test this hypothesis? | medium | T2

V1-Q6 | P3:right col, eq 2 | [REDACTED: verbatim source quotation; see the source paper via its DOI] | PMB deprotection is demonstrated only for the model compound 5→25 — is CAN-mediated deprotection compatible with the full range of functional groups in Scheme 3, particularly the N-Boc group in 14, the aryl chloride in 9, aryl bromide in 10, and the TIPSO-bearing substrate 16? | medium | T2

V1-Q7 | P4:left col, para beginning "Finally, to demonstrate" | [REDACTED: verbatim source quotation; see the source paper via its DOI] | What is the overall yield of the three-step synthesis of (R)-mephenytoin (amide 27 → substrate 28 → intermediate 29 → final product 30), and what is the measured ee of the final product 30 (not only of intermediate 29)? | medium | T1

V1-Q8 | P3:right col, eq 2 | [REDACTED: verbatim source quotation; see the source paper via its DOI] | By what method was the absolute configuration of (S)-25 established — was X-ray crystallography, VCD spectroscopy, or comparison to a chemically synthesized standard of known absolute configuration used? The paper cites SI (ref 16) for this assignment but the method of determination is not stated in the main text. | medium | T1

V1-Q9 | P3:left col, para beginning "Consistent with a Heck-like pathway" | [REDACTED: verbatim source quotation; see the source paper via its DOI] | What is the structural difference between the tetrasubstituted alkene starting materials for 18 (99% yield, 63% ee) and 19 (33% yield, 83% ee) at 75 °C? Were systematic optimization studies performed specifically for tetrasubstituted alkene substrates, and is the high temperature compatible with all functional groups? | medium | T1

V1-Q10 | P3:left col, para beginning "Furthermore, the amount of aza-Wacker product" | [REDACTED: verbatim source quotation; see the source paper via its DOI] | Is there direct evidence establishing a causal mechanistic link between aza-Wacker product formation and Pd(II) precatalyst reduction (e.g., using an independently pre-reduced Pd(0) source or a pre-formed Pd(0)/L1 complex), rather than a coincidental correlation between Pd loading and byproduct yield? | high | T2

V1-Q11 | P2:right col, para beginning "A more focused screen" | [REDACTED: verbatim source quotation; see the source paper via its DOI] | The paper describes only the matched/mismatched pair comparison in text; is there data from the full 48-ligand HTE showing a systematic relationship between ligand features (BINOL substitution, amine component stereochemistry) and enantioselectivity, or is only the lead ligand outcome reported? | medium | T2

V1-Q12 | P2:right col, para beginning "Control experiments proved" | [REDACTED: verbatim source quotation; see the source paper via its DOI] | What specific control reactions were run (e.g., no Pd, Lewis acid substitution, thermal conditions, radical initiators), and what was the outcome of each? The reference to SI (ref 16) defers this information from the main text. | low | T1 [deferred to SI — experiments performed]

V1-Q13 | P4:left col, Scheme 3 right col, compound 10 | [REDACTED: verbatim source quotation; see the source paper via its DOI] | What are the specific byproducts from competitive Ar–Br activation observed for substrate 10, and was the yield reduction quantified relative to the standard conditions? Could the use of Pd(0) precatalysts suppress Ar–Br oxidative addition as a competing pathway? | medium | T2

V1-Q14 | P2:right col, para beginning "Our initial studies" | [REDACTED: verbatim source quotation; see the source paper via its DOI] | What level of DFT theory (functional, basis set, solvent correction) was used for the conformational energy calculations (ΔG°rel = 5.7 kcal/mol and 0.6 kcal/mol)? These values are central to the rationale for N-substitution but the computational details are relegated to SI (ref 16). | medium | T2

**Scope failure example verification:**
Compound 20 (N-Ph, 0% yield) is an explicit failure and is shown in Scheme 3; the authors attribute it to electronic factors with DFT support but no experimental corroboration.
No explicit failures with 0% yield or trace yield are shown within the scope table for the functional group series (6–19), spirocyclic (11–14), and alkene substituent (15–17) series — the full failure cases are deferred to SI.

**Dropped Quantitative Benchmark check:**
The introduction cites Archambeau's synthesis (ref 9) with specific ee values "40–88% ee." The results section does not include a direct numerical comparison of yield and ee on an identical substrate between the present method and Archambeau's route. This qualifies as a C-item candidate (Dropped Quantitative Benchmark) — no side-by-side comparison on a common substrate is presented despite citing numerically specific prior art.

---

> **Public-cut redaction notice**: verbatim quotations from the analysed papers in this file have been replaced by `[REDACTED: …]` markers (rules in the repository README). The unredacted file is in the reviewer version of the deposit.
